Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Profit After Tax (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Profit After Tax for 6 consecutive years, with -$79.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax rose 3.65% year-over-year to -$79.1 million, compared with a TTM value of -$224.8 million through Sep 2025, up 16.8%, and an annual FY2024 reading of -$220.7 million, down 5.9% over the prior year.
  • Profit After Tax was -$79.1 million for Q3 2025 at Autolus Therapeutics, down from -$47.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$27.0 million in Q4 2022 and bottomed at -$82.1 million in Q3 2024.
  • Average Profit After Tax over 4 years is -$51.7 million, with a median of -$45.8 million recorded in 2023.
  • The sharpest move saw Profit After Tax tumbled 186.1% in 2023, then soared 64.19% in 2024.
  • Year by year, Profit After Tax stood at -$27.0 million in 2022, then crashed by 186.1% to -$77.2 million in 2023, then skyrocketed by 64.19% to -$27.6 million in 2024, then crashed by 186.12% to -$79.1 million in 2025.
  • Business Quant data shows Profit After Tax for AUTL at -$79.1 million in Q3 2025, -$47.9 million in Q2 2025, and -$70.2 million in Q1 2025.